key: cord-0928430-zrd7yicj authors: Rieder, Marina; Wirth, Luisa; Pollmeier, Luisa; Jeserich, Maren; Goller, Isabella; Baldus, Niklas; Schmid, Bonaventura; Busch, Hans-Joerg; Hofmann, Maike; Kern, Winfried; Bode, Christoph; Duerschmied, Daniel; Lother, Achim title: Serum ACE-2, angiotensin II, and aldosterone levels are unchanged in patients with COVID-19 date: 2020-10-12 journal: Am J Hypertens DOI: 10.1093/ajh/hpaa169 sha: 6f8d03baf386f9119b1eb77d8ef9a02d6fa03877 doc_id: 928430 cord_uid: zrd7yicj BACKGROUND: The role of the renin-angiotensin-aldosterone system in COVID-19 is controversially discussed. SARS-CoV-2 enters host cells by binding to angiotensin-converting enzyme 2 and activity of the renin-angiotensin-aldosterone system may affect susceptibility to SARS-CoV-2 infection and outcome of patients with COVID-19. METHODS: In this prospective single-center study, we determined the serum levels of ACE-2, angiotensin II and aldosterone in patients with COVID-19 compared to control patients presenting with similar symptoms in the emergency unit. RESULTS: We analyzed serum samples from 24 SARS-CoV-2 positive and 61 SARS-CoV-2 negative patients. SARS-CoV-2 positive and control patients did not differ in baseline patients characteristics, symptoms and clinical presentation. Mean serum concentrations of ACE2, angiotensin II, and aldosterone did not differ between the SARS-CoV-2 positive and the control group. In line with this, serum potassium as surrogate parameter for RAAS activity and blood pressure were similar in both groups. CONCLUSIONS: In summary, we did not find evidence for altered RAAS activity including angiotensin II, aldosterone, or potassium levels, and blood pressure in patients with COVID-19. M a n u s c r i p t 2 Abstract: The role of the renin-angiotensin-aldosterone system in COVID-19 is controversially discussed. SARS-CoV-2 enters host cells by binding to angiotensin-converting enzyme 2 and activity of the renin-angiotensin-aldosterone system may affect susceptibility to SARS-CoV-2 infection and outcome of patients with COVID-19. In this prospective single-center study, we determined the serum levels of ACE-2, angiotensin II and aldosterone in patients with COVID-19 compared to control patients presenting with similar symptoms in the emergency unit. We analyzed serum samples from 24 SARS-CoV-2 positive and 61 SARS-CoV-2 negative patients. SARS-CoV-2 positive and control patients did not differ in baseline patients characteristics, symptoms and clinical presentation. Mean serum concentrations of ACE2, angiotensin II, and aldosterone did not differ between the SARS-CoV-2 positive and the control group. In line with this, serum potassium as surrogate parameter for RAAS activity and blood pressure were similar in both groups. In summary, we did not find evidence for altered RAAS activity including angiotensin II, aldosterone, or potassium levels, and blood pressure in patients with COVID-19. A c c e p t e d M a n u s c r i p t 3 A c c e p t e d M a n u s c r i p t 4 Background: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with significant morbidity and mortality worldwide. Since SARS-CoV-2 enters host cells by binding to angiotensinconverting enzyme 2 (ACE2) 1 , the role of the renin-angiotensin-aldosterone system (RAAS) and the safety or RAAS inhibitors in COVID-19 is controversially discussed 2,3 . The formation of angiotensin II out of angiotensin I is mediated by angiotensin-converting enzyme (ACE). Angiotensin II acts via the angiotensin II receptor type 1 as a potent vasoconstrictor. In addition, it promotes the secretion of aldosterone from the adrenal gland. Both, angiotensin II and aldosterone, increase blood pressure and drive adverse tissue remodeling. Accordingly, inhibitors of the RAAS such as ACE inhibitors or angiotensin receptor blockers (ARB) are frequently prescribed drugs for hypertension and heart disease. However, the detrimental effects of ACE and angiotensin II are not limited to the cardiovascular system. Angiotensin II promotes pulmonary vasoconstriction and vascular permeability, induces the production of inflammatory cytokines and extracellular matrix synthesis, and thus contributes to many of the key characteristics of acute respiratory distress syndrome (ARDS) 4, 5 . In contrast to ACE, ACE 2 mediates the breakdown of angiotensin I or angiotensin II to angiotensin-(1-9) or angiotensin-(1-7), respectively, that act as potent vasodilators 6 . Different levels of interaction between the RAAS and SARS-CoV-2 have been proposed, suggesting that ACE2 in COVID-19 may be a double-edged sword 2,5 : On the one hand, age, comorbidities, or treatment with RAAS inhibitors may alter ACE2 expression and thereby potentially increase SARS-CoV-2 susceptibility of respective patient groups 7, 8 . Supplementing soluble ACE2 has been suggested as measure to block SARS-CoV-2 cell entry 9 . On the other hand, RAAS inhibition or increased plasma ACE2 expression may break down angiotensin II and attenuate its detrimental effects on ARDS in COVID-19 10 . Finally, SARS-CoV-2 infection itself may alter ACE2 expression, thus modulating angiotensin II and aldosterone levels. In this study, we determined the serum levels of ACE-2, angiotensin II In summary, we did not find evidence for altered RAAS activity including angiotensin II, aldosterone, or potassium levels, and blood pressure in patients with COVID-19. Our study supports a very recent report describing unchanged ACE2 activity in patients with COVID-19 with or without ACE inhibitors or ARBs 11 . Using a similar approach, Kintscher It is a limitation to our study, that most of the patients included had non-severe COVID-19. A smaller study from Wuhan, China, had reported that plasma levels of angiotensin II were increased in 12 cases of severe COVID-19 pneumonia compared to healthy controls and associated with disease severity 13 . More recently, it has been shown that severity of ARDS in patients with COVID-19 was associated with an increase in blood pressure and decrease in serum potassium concentrations, suggesting high RAAS activity 14 . On the other hand, we consider it a key strength of this study that we compared patients with COVID-19 to patients with other diseases but comparable characteristics and severity, not healthy individuals. This enables us to distinguish the proposed specific activation of the RAAS by SARS-CoV-2 interaction with ACE2 from unspecific activation in severe disease. Increased angiotensin concentrations have been associated with adverse outcomes of patients with ARDS 15 or heart disease 16 earlier, and our findings support the interpretation that this is not specific for COVID-19. The findings from this study are in line with a series of retrospective registries that demonstrated no effect of RAAS inhibitors on SARS-CoV-2 susceptibility or outcome of patients with COVID-19 8 . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor COVID-19 and ACEI/ARB: Not Associated? Hypertension and COVID-19 Recombinant human ACE2: acing out angiotensin II in ARDS therapy Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review Hypertension: renin-angiotensin-aldosterone system alterations Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors COVID-19: ACE2centric Infective Disease? Could the smoking gun in the fight against COVID-19 be the (rh)ACE-2? The European respiratory journal 2020 Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives Poglitsch M, Mockel M. Plasma Angiotensin Peptide Profiling and ACE2-Activity in COVID-19 Patients 12 Aldosterone LC-MS/MS Assay-Specific Threshold Values in Screening and Confirmatory Testing for Primary Aldosteronism Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients Circulating angiotensin peptides levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study Elevated Angiotensin 1-7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients With Heart Failure A c c e p t e d M a n u s c r i p t